Awani Review

Complete News World

Johnson & Johnson is "confident" about their vaccine

Johnson & Johnson is “confident” about their vaccine

(New York) Johnson and Johnson (J&J) are still “very confident” of the COVID-19 vaccine and we hope to find a solution “very soon” with regulators on its use, which is currently suspended in Europe and the United States, its chief financial officer said Tuesday.




France Media

The European Medicines Agency (EMA) is due to give its opinion on Tuesday on the vaccine developed by J&J after a rare occurrence of serious blood clots, while White House Medical Adviser Anthony Fauci said on Sunday that a ruling in the United States is expected to be published by Friday. .

“We remain very confident” and “we hope that the balance between benefits and risks will work in our favor,” Joseph Walker said in an interview with CNBC.

“We are working with the regulators to make sure they have all the information they need to make their decisions,” he said.

As Mr. Walck, speaking on The Guardian noted, “We expect to get very soon, possibly this weekend, from Europe and the FDA (US Medicines Agency, Editor’s Note) how to go forward” on the occasion of publishing the group’s quarterly results.

The company’s CEO Alex Gorsky said in a conference call on Tuesday that the group stands “ready to resume delivery of the COVID-19 vaccine in Europe” and is expected to “fulfill its commitment to deliver 200 million doses to the European Union, Norway and Iceland”.

In the statement detailing the company’s financial performance, J&J did not specifically mention the vaccine, which it is selling at cost, other than indicating that it sold for $ 100 million in the United States.

See also  COVID-19: A stable record on Bas-Saint-Laurent

The group is also facing production problems at a plant in Baltimore, Maryland, run by Emergent BioSolutions, with a range of vaccine doses that do not meet quality standards.

The US Food and Drug Administration (FDA) has requested that production at this plant be suspended until the inspection is completed.

Mr. Walck emphasized that if the regulatory process went well, we would be able to fulfill all of our contractual obligations (regarding vaccine delivery, Editor’s Note), in the United States, but also around the world.